

By Speed Post/ Special Messenger/e-mail

F. No. 19(719)/2016/DP/NPPA/Div.II
भारत सरकार
Government of India
रसायन एवं उर्वरक मंत्रालय
Ministry of Chemical and Fertilizers
औषध विभाग
Department of Pharmaceuticals
राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण
National Pharmaceutical Pricing Authority


5th/3rd Floor,
YMCA cultural Centre Building
1, Jai Singh Road, N. Delhi- 11001
Dated 21.4.2017

OFFICE MEMORANDUM

Subject: 4th meeting of the Committee of Experts under Para 11(3&4) of DPCO 2013

The Fourth meeting of the committee of Experts constituted under para 11(3 & 4) of DPCO, 2013 which was scheduled to be held on **19.04.2017 (Wednesday) at 11.00 AM** could not be completed & now continue to be held on **02.5.2017 (Tuesday) at 10:00AM** in the conference room of National Pharmaceuticals Pricing Authority (NPPA), 3rd Floor, YMCA Cultural Center Building, 1, Jai Singh Road, New Delhi - 110001 to consider 9 cases as on date (Annexure) under the provision contained in Para 11 (3 & 4), which states that:

- (a) Notwithstanding anything contained in sub-paragraphs (1) and (2), in case of injections or inhalation or any other medicine for which dosage form or strength or both are not specified in the Schedule-I of the Drugs (Prices Control) Order, 2013, the Government may fix and notify separate ceiling price or retail price for such formulations with specific therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely liquid, gaseous or any other form, in the unit dosage as the case may be, conforming to Indian Pharmacopeia or other standards as specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder for the same formulation.
 - (b) The Government shall form a Committee of Experts, as it may deem fit, within a period of fifteen days from the date of issue of this order, to recommend fixing of separate ceiling price of scheduled formulations or retail price of a new drug as per the above parameters.
2. Moreover, any other issue(s) relating to above mention subject, with the permission of Chair will also be taken up/discussed in the meeting.
 3. It has been observed that the presence of the members of the committee is very poor, thus, all the nominated members are requested to be present without fail.
 4. You are, therefore, requested to make it convenient to attend the meeting.


(ए. के. खुराना)
निदेशक

Encl: As above.

To,

The Members of the Committee:-

1. Prof. Y. K. Gupta, Head, Department of Pharmacology, AIIMS, New Delhi
2. Prof. V.K. Behal, Head of Department of Cardiology, AIIMS, New Delhi or representative
3. Dr. Naval K Vikram, Prof., Department of Medicine, AIIMS, New Delhi or representative
4. Prof. Rakesh Yadav, Department of Cardiology, AIIMS, New Delhi or representative
5. Prof. Balram Bhargava, Department of Cardiology, AIIMS, New Delhi or representative
6. Sh. Chandrasheka Ranga, Dy. DC (I), O/o Drug Controller General of India, Ministry of Health and Family Welfare, New Delhi
7. Shri P.K. Abdul Kareem, Add. Economic Adviser, O/o Department of Economic Affairs, Economic Division, North Block, New Delhi

8. Shri D. P. Pathak, Director, Delhi Institute of Pharmaceutical Science and Research (DIPSAR) or representative
9. Dr. Sarita Dhawan, Add. Director /Director, CGHS, New Delhi or representative
10. Sh. Mohammad Ameer, Consultant, National Health System Resource Centre
11. Sh. Vijay Kumar, Scientist 'G', Indian Council of Medical Research or representative
12. Sh. Rakesh Pandey, Dy. Director, O/o CAC, Deptt of Expenditure, MoF

Copy to:

1. PPS to Chairman, NPPA
2. PPS to MS, NPPA
3. PPS to Adviser (cost), NPPA

List of issue for discussion under para 11(3) of DPCO, 2013

Review cases		
Sl. No.	Name of the company	Formulation
1	Cipla Ltd	Budesonide Inhalation 100mcg & 200mcg
Representation cases		
Sl. No.	Name of the company	Formulation
1	1. Serum Institute of India 2. Biological E. Ltd	DPT vaccine
2	1. Serum Institute of India 2. Biological E. Ltd 3. Panacea Biotec	DPT+Hib+ Heb B Vaccine
3	1. Serum Institute of India 2. Biological E. Ltd 3. Sanofi Pasteur India	Hepatitis B vaccine
4	1. Alber David Ltd 2. The Pharmaceutical form-fill-seal association of India 3. Fresenius Kabi India Pvt Ltd	Glucose 10% Injection
5	Glenmark Pharmaceuticals Ltd	Digihaler FB 100/200/400 and Budesonide/ Formoterol 9100/6, 200/6, 400/6 mcg)
6	M/s Boston Scientific India Ltd	Stents Synerty Evrolimus Eluting Platrinum Chromium Coronary Stent with Bio-Absorbable Polymer Systems
7	M/s Boston Scientific India Ltd	Stents Promus Premier Everolimus -Eluting Coronary Stent system
8	M/s Envision Scientific Pvt Ltd	Stents Albuminus DES+- An Abluminal coated Sirolimus Eluting Coronary Stent system